Skip to main content
915 TLDR
Health
1 read

Juárez Launches Campaign to Combat Rickettsiosis Amid Rising Cases

KVIA••Heriberto Perez Lara
Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

Read Original

AI Summary

The City of Juárez has initiated a campaign aimed at curbing the spread of rickettsiosis, an insect-borne disease that has resulted in over 20 deaths this year. The Juárez Ecology Department reported that the disease, primarily affecting young adults aged 25-44, has a high mortality rate of 44% due to delayed diagnoses. With critical levels of rickettsiosis reported in 2026, local health officials are working closely with their El Paso counterparts to implement preventive measures. Residents are encouraged to stay informed about the disease and take precautions to avoid tick bites.

Key Details: • Over 20 deaths related to rickettsiosis reported in 2023. • High mortality rate of 44% due to late diagnosis. • Most affected demographic: young adults aged 25-44. • Residents should take preventive measures against tick bites.

border health juarez campaign rickettsiosis

People & Organizations

El PasoCiudad JuárezJuárez Ecology Department

Related Articles

KTSM•Jun 24

White House Addresses Rumors on Trump's Access to Eli Lilly's Obesity Drug

The White House has clarified that speculation regarding former President Donald Trump's access to the experimental obesity drug retatrutide, produced by Eli Lilly, is unfounded. Although the drug is not yet approved by the FDA, it can be accessed through a compassionate use program for patients with life-threatening conditions. This clarification is significant as it highlights the ongoing discussions around drug access and approval processes, particularly for high-profile individuals. The compassionate use program allows for limited access to unapproved treatments, but it is not indicative of broader availability.

Health
1 min read
KTSM•Jun 24

White House Denies Trump Received Experimental Obesity Drug Access

The White House has dismissed rumors suggesting that former President Donald Trump was granted access to the experimental obesity drug retatrutide, produced by Eli Lilly, under a compassionate use program. This program typically allows patients with life-threatening conditions to access unapproved treatments. While the drug is not yet FDA-approved, it has been made available to select individuals under specific circumstances. The clarification from the White House highlights ongoing discussions around drug access and the implications of compassionate use policies.

Health
1 min read
KTSM•Jun 24

El Paso Welcomes Its First Dedicated Burn Center at UMC

University Medical Center of El Paso has launched the area's inaugural dedicated burn center, aimed at providing specialized care for burn victims. This facility is led by Dr. Philip Fidler, a nationally recognized expert in trauma and burn treatment. The establishment of this center is significant for the community, as it addresses a critical need for advanced burn care in the region. The center is expected to enhance recovery outcomes for patients suffering from severe burns and injuries, marking a major advancement in local healthcare resources.

Health
1 min read
KTSM•Jun 24

UMC Launches El Paso's First Specialized Burn Treatment Center

University Medical Center (UMC) in El Paso is making significant strides in establishing the region's first dedicated burn center, led by Dr. Philip Fidler, a nationally recognized expert in trauma and burn surgery. This initiative is crucial for providing specialized care for burn victims, enhancing treatment options available locally. The center aims to improve recovery outcomes for patients suffering from severe burns and related injuries. UMC's commitment to advanced medical care underscores its role in addressing critical health needs in the community.

Health
1 min read